Duality Advisers LP Sells 28,723 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Duality Advisers LP lowered its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 23.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 95,148 shares of the company’s stock after selling 28,723 shares during the period. Duality Advisers LP’s holdings in Vir Biotechnology were worth $957,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Vontobel Holding Ltd. lifted its holdings in Vir Biotechnology by 94.2% during the third quarter. Vontobel Holding Ltd. now owns 50,819 shares of the company’s stock valued at $476,000 after purchasing an additional 24,656 shares during the last quarter. CWM LLC lifted its stake in shares of Vir Biotechnology by 882.7% during the 3rd quarter. CWM LLC now owns 7,488 shares of the company’s stock valued at $70,000 after buying an additional 6,726 shares in the last quarter. SG Americas Securities LLC bought a new position in Vir Biotechnology in the 3rd quarter worth approximately $838,000. State of Alaska Department of Revenue raised its holdings in Vir Biotechnology by 205.5% during the 3rd quarter. State of Alaska Department of Revenue now owns 153,494 shares of the company’s stock valued at $1,438,000 after acquiring an additional 103,246 shares during the period. Finally, Everence Capital Management Inc. raised its holdings in Vir Biotechnology by 110.7% during the 3rd quarter. Everence Capital Management Inc. now owns 21,430 shares of the company’s stock valued at $201,000 after acquiring an additional 11,260 shares during the period. Institutional investors own 65.32% of the company’s stock.

Insider Buying and Selling at Vir Biotechnology

In other news, EVP Phillip Pang sold 3,321 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $10.24, for a total value of $34,007.04. Following the transaction, the executive vice president now owns 264,679 shares of the company’s stock, valued at approximately $2,710,312.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, Director George A. Scangos sold 10,878 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $10.24, for a total value of $111,390.72. Following the completion of the sale, the director now owns 157,611 shares in the company, valued at approximately $1,613,936.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Phillip Pang sold 3,321 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $10.24, for a total transaction of $34,007.04. Following the transaction, the executive vice president now owns 264,679 shares in the company, valued at $2,710,312.96. The disclosure for this sale can be found here. Insiders sold a total of 152,831 shares of company stock worth $1,525,844 over the last three months. 18.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on VIR. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday, March 15th. JPMorgan Chase & Co. raised their target price on Vir Biotechnology from $9.00 to $10.00 and gave the stock a “neutral” rating in a research note on Friday, February 23rd. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.38.

Vir Biotechnology Price Performance

NASDAQ:VIR opened at $8.13 on Wednesday. Vir Biotechnology, Inc. has a 52-week low of $7.72 and a 52-week high of $27.48. The stock has a fifty day moving average of $10.07 and a 200 day moving average of $9.61.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.86) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.28. The firm had revenue of $16.80 million during the quarter, compared to the consensus estimate of $11.18 million. Vir Biotechnology had a negative return on equity of 34.92% and a negative net margin of 713.69%. The company’s revenue for the quarter was down 66.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.76) EPS. Equities analysts predict that Vir Biotechnology, Inc. will post -4.04 earnings per share for the current fiscal year.

About Vir Biotechnology

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.